Exclusive Option Agreement for NXP001 in Oncology

  • Date 28 Sep 2020

Nuformix a pharmaceutical development company focused on unlocking the therapeutic potential and value of known
drugs to develop novel medicines to provide enhanced benefit, announces it has signed an exclusive
option agreement with Oxilio Ltd (“Oxilio”)

Read more

Join an ambitious, supportive community of world-class scientists, engineers and entrepreneurs

Read more